Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

Jonathan R. Strosberg, MD
Published: Wednesday, May 03, 2017



Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Although there are many emerging therapies for NETs, there is little to no information on sequencing. Sequencing may give more information on what works best in the general population, but better predictive factors are needed in such a heterogeneous patient population.

Predictive factors are also needed to help determine which patients will best respond to immunotherapy, as it will probably be a small population, Strosberg says.
 


Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Although there are many emerging therapies for NETs, there is little to no information on sequencing. Sequencing may give more information on what works best in the general population, but better predictive factors are needed in such a heterogeneous patient population.

Predictive factors are also needed to help determine which patients will best respond to immunotherapy, as it will probably be a small population, Strosberg says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Publication Bottom Border
Border Publication
x